Pacemaker Economics: Why the Market Underrates Them
Birr Castle nearly stole the Juddmonte last year. This time an honest tempo did the damage.
Pacemakers are one of the most familiar sights in top-level Flat racing, yet the market rarely prices in the chaos they can cause. Their job is to force a true gallop, but every so often that gallop reshapes the result, and occasionally the pacemaker itself is the one left standing. Wednesday’s Juddmonte International was a case study in both.
What happened at York
The 2026 Juddmonte was set up as a duel between the two market principals, and the pace unpicked it. A searching tempo forced along by Hawk Mountain worked against the favourites. Constitution River, sent forward into the pace, could find no extra once headed and faded in the final furlong. The race fell instead to the closers.
Item, sent off at 10/1 in our pre-race verdict, got the better of Almaqam, a 14/1 shot, with both of the big two beaten. One of the world’s highest-rated horses, Ombudsman, could finish only fourth. The soft ground did the pair no favours either, but the tactical picture told its own story.
Why the market underrates it
The mechanics are simple enough. A strong, uncontested gallop burns the finishing kick out of hold-up horses and closers, and it can turn a race that looked a two-horse affair into a scramble. Every now and then the front-running pacemaker is not collared at all and hangs on for a place, or even the win, at odds nobody wanted.
There is recent evidence for both outcomes. Twelve months ago Ombudsman’s own pacemaker, Birr Castle, ran his rivals ragged and clung on for third at 150/1, a price that made no sense on form but every sense on tactics. Better still, in 2025 Qirat went one further, winning the Sussex Stakes outright as a pacemaker at 150/1, one of the biggest-priced Group 1 wins in British racing history.
How often it really pays
A word of caution before anyone treats this as a system. Racing Post’s reckoning is that British Group 1s produced roughly two pacemaker winners across two years, at 22/1 and 150/1, against a long-term average of comfortably fewer than one a year. In a sample of races where a pacemaker was clearly in the field, that still translated into a healthy rate of return, but the base rate is tiny.
This is the honest version of the angle. Most pacemakers do their job and drop away, and very few are trained to win. What Wednesday underlined is not a betting formula but a warning: in a race with real early pace, the form book is only half the story, and the closers waiting off it can be the value. Occasional each-way interest, not a strategy.
